Aryl ureas with angiogenisis inhibiting activity
This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
1. A method of blocking tumor angiogenesis in a human or other mammal comprising administering to a human or other mammal with a tumor of the liver an effective amount of the compound N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea of the formula below or a pharmaceutically acceptable salt thereof
wherein the tumor of the liver is characterized by abnormal angiogenesis or hyperpermiability processes, which are mediated by KDR(VEGFR-2).
2. A method as in claim 1 wherein the compound N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea or a pharmaceutically acceptable salt thereof is administered simultaneously with another angiogenesis inhibiting agent to a human or other mammal with a tumor of the liver in the same formulation or in separate formulations.
3. A method as in claim 1 wherein the tumor that is treated is characterized by abnormal angiogenesis or hyperpermiability processes, which are not raf-mediated.
4. A method as in claim 1 wherein the tumor that is treated is characterized by abnormal angiogenesis or hyperpermiability processes, which are not p38-mediated.
5. The method of claim 1 , wherein herein the effective amount of the compound N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea of the formula below is between 0.01 to 200 mg/Kg of total body weight
6. A method of blocking tumor angiogenesis in a human comprising administering to a human with a tumor of the liver an effective amount of the compound N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea tosylate, wherein the tumor of the liver is characterized by abnormal angiogenesis or hyperpermiability processes, which are mediated by KDR(VEGFR-2).
7. A method as in claim 6 wherein the tumor of the liver that is treated is characterized by abnormal angiogenesis or hyperpermiability processes, which are neither raf-mediated nor p38-mediated.
8. The method of claim 6 , wherein the effective amount of the compound N-(4-chloro-3-(trifluoromethyl)phenyl)-N′-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea tosylate is between 0.01 to 200 mg/Kg of total body weight.